Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Director | October 21, 2025 | October 22, 2025 |
| GERON CORPGERN · Entity 4989 | Director | May 20, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date October 21, 2025 · Filed October 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.98 · Expires 2035-10-21 | Direct | 53,000 |
Reported balance
After 2025-10-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-21 · Grant · Acquired 53,000 · Balance 53,000 F1: The stock option vests over three (3) years at a rate of 1/36th each month. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests over three (3) years at a rate of 1/36th each month.
GERON CORP
Report date May 20, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-05-19 | Direct | 220,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 220,000 · Balance 220,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
REATA PHARMACEUTICALS INC
Report date September 26, 2023 · Filed September 26, 2023
Section 16 reporting ended · disclosed 2023-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 1
1 source rowRow 1 · 2023-09-26 · Disposition to issuer · Disposed 33,805 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.29 · Expires 2031-01-04 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-26 · Disposition to issuer · Disposed 16,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.32 · Expires 2032-01-03 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-26 · Disposition to issuer · Disposed 70,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.71 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-26 · Disposition to issuer · Disposed 63,650 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.75 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-26 · Disposition to issuer · Disposed 71,300 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.73 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-26 · Disposition to issuer · Disposed 34,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.73 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-26 · Disposition to issuer · Disposed 17,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.73 · Expires 2029-01-02 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-26 · Disposition to issuer · Disposed 17,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $207.20 · Expires 2030-01-02 | Direct | 0 |
Reported balance
After 2023-09-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-26 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2) F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. ("Biogen") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, "Common Stock") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the "Merger Consideration"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, (Continued in Footnote 2)
F2: (Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 16,991 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2020 Filed Nov 10, 2020 22:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 60,000 | $21.05 | $1,263,000.00 |
DisclosureSEC source: 0001209191-20-057705 · doc4.xml · derivative · entry 5 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A common stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 22:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001209191-20-057705 · doc4.xml · derivative · entry 4 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Class B common stock · 60,000 shares Expires 2026-09-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020. F3 · derivative.exercise_date: One quarter of the options vested on September 6, 2017 and then in twelve equal quarterly installments thereafter, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 22:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 30,000 | $175.00 | $5,250,000.00 |
DisclosureSEC source: 0001209191-20-057705 · doc4.xml · nonDerivative · entry 3 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 22:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 30,000 | $150.01 | $4,500,300.00 |
DisclosureSEC source: 0001209191-20-057705 · doc4.xml · nonDerivative · entry 2 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 22:30 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-057705 · doc4.xml · nonDerivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2020. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:11 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000886744-20-000047 · edgar.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 19:47 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $207.20 | $0.00 |
DisclosureSEC source: 0001209191-20-001618 · doc4.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Class B common stock · 24,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 2, 2020, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 17,250 | $0.00 Strike: $55.73 | $0.00 |
DisclosureSEC source: 0001209191-19-056100 · doc4.xml · derivative · entry 2 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Underlying: Class B common stock · 17,250 shares Expires 2029-01-02 F1 · derivative.exercise_date: On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · balance_after: On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date. Read SEC document |
| October 14, 2019 Filed Nov 12, 2019 22:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 17,250 | $0.00 Strike: $55.73 | $0.00 |
DisclosureSEC source: 0001209191-19-056100 · doc4.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Underlying: Class B common stock · 17,250 shares Expires 2029-01-02 F1 · derivative.exercise_date: On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · balance_after: On January 2, 2019, the reporting person was granted an option to purchase 69,000 shares of Class B common stock. As previously reported, the option vests as to 34,500 shares in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. On October 14, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on January 14, 2020, subject to continued service through each vesting date. On November 11, 2019, based on the satisfaction of certain performance criteria, the option vested as to 4,312 shares and the option was set to vest as to 12,938 shares in twelve equal quarterly installments beginning on February 11, 2020, subject to continued service through each vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:18 UTC | GERON CORP GERN · Entity 4989 | GrantSrock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000886744-19-000060 · edgar.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| March 26, 2019 Filed Mar 29, 2019 00:23 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0000886744-19-000041 · edgar.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-03-25 F1 · derivative.exercise_date: This option vests in a series of three equal consecutive annual installments commencing from March 26, 2019, subject to the non-employee director providing continuous service to the Company through each vesting date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 19:15 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 34,500 | $0.00 Strike: $55.73 | $0.00 |
DisclosureSEC source: 0001209191-19-000757 · doc4.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Class B common stock · 34,500 shares Expires 2029-01-02 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| December 06, 2017 Filed Dec 7, 2017 20:43 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 71,300 | $0.00 Strike: $24.75 | $0.00 |
DisclosureSEC source: 0001209191-17-064372 · doc4.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,300 Underlying: Class B common stock · 71,300 shares Expires 2027-12-06 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on March 6, 2018, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 20:56 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $22.57 | $0.00 |
DisclosureSEC source: 0001209191-16-154121 · doc4.xml · derivative · entry 1 Bir Dawn Carter · CIK 0001688712 · VP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class B common stock · 40,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The options vest in twenty equal quarterly installments beginning on March 7, 2017, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.